Arcturus Therapeutics: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Tuesday reported a loss of $29.1 million in its fourth quarter.
The San Diego-based company said it had a loss of $1.03 per share.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 92 cents per share.
The pharmaceutical company posted revenue of $7.2 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $14.4 million.
For the year, the company reported that its loss narrowed to $65.8 million, or $2.40 per share. Revenue was reported as $82 million.
Arcturus Therapeutics shares have climbed 30% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.94, a decrease of 49% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ARCT at https://www.zacks.com/ap/ARCT
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Italy's Fineco says will use AI to boost new client growth under plan to 2029
EUR/USD: Ongoing tensions continue to weigh on the euro – Commerzbank
USAC's Fostung Tungsten Deposit: Evaluating a North American Source Amidst a Constrained Market
Bitcoin Demand Returns As Gold Faces Safe-Haven Test — Why $70,000 Is Critical Now
